Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT00988715 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 | 17 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 |
| NCT01947322 | Haploidentical NK-cell Infusion in Acute Myeloid Leukemia(NK) | completed | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01169012 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | completed | Phase 1 | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01141725 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | completed | Phase 1 / Phase 2 | 39 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01606579 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 49 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01048827 | Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen(Busulfan) | completed | Phase 1 | 12 | University of California, San FranciscoOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT01130506 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2017 | clinicaltrials |
| NCT01961765 | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00839982 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01677780 | An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies | completed | Phase 1 | 11 | Hoffmann-La RocheINDUSTRY | 3 | Jul 7, 2017 | clinicaltrials |
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | completed | Phase 1 / Phase 2 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01820624 | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 12 | Paolo Caimi, MDOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT01435343 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | completed | Phase 1 / Phase 2 | 55 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00943943 | Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01398501 | Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT00093743 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | completed | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01779843 | Alisertib for Acute Myeloid Leukemia | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00394381 | Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 17 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02071927 | Study of the Glutaminase Inhibitor CB-839 in Leukemia | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT02096289 | Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia(THORIDAL) | completed | Phase 1 | 13 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT01635296 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 43 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01641250 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 44 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT01174888 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 34 | Alison WalkerOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00316030 | Study of Bexarotene in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 54 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 8, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00428909 | Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 21, 2016 | clinicaltrials |
| NCT01075425 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 41 | Virginia Commonwealth UniversityOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT00529360 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | completed | Phase 1 / Phase 2 | 32 | New York Medical CollegeOTHER | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01681537 | Lenalidomide Plus Chemotherapy for AML | completed | Phase 1 | 36 | Massachusetts General HospitalOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02040506 | A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML | completed | Phase 1 | 19 | Igenica Biotherapeutics, Inc.INDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00892190 | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | completed | Phase 1 | 9 | University of PittsburghOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01795378 | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation(DNKI-II) | completed | Phase 1 / Phase 2 | 56 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT01397799 | Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 24 | Kinex Pharmaceuticals Inc.INDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00039117 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00459212 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00303290 | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Sep 15, 2017source: clinicaltrials